Manufacture and Supply. BMS shall Manufacture or have Manufactured the BMS Study Drug in reasonable quantities needed, and at the points in time as agreed to by the Parties, for the Combined Therapy Clinical Trial, and shall supply such BMS Study Drug as commercially labeled or unlabeled vials to the Recipient or its designee for use solely in the Combined Therapy Clinical Trial. The Recipient will at its sole expense, package and label the BMS Study Drug for use in the Combined Therapy Clinical Trial to the extent necessary. The cost of Manufacture and supply (including shipping, taxes and duty, if applicable) of the BMS Study Drug for the Combined Therapy Clinical Trial shall be borne solely by BMS, and BMS shall bear the risk of loss for such quantities of BMS Study Drug until delivery of such quantities of BMS Study Drug to the Recipient or its designee. BMS shall also be responsible for the

Viela shall be responsible for Manufacturing and supplying the Product to MTPC, its Affiliates or its Sublicensees in compliance with Applicable Laws and in a manner suitable for Development, Commercialization and Final Manufacturing activities in the Territory during the Term. Viela shall use commercially reasonable efforts to reduce the Fully-Burdened Costs. Such efforts will not need to include: ​.

The Parties intend to enter into one or more agreements that will govern the terms of manufacture and supply of CTL Products and New CTL Products and Program [ * ], including specific [ * ] Products for clinical supply for use in development activities, including clinical trials to be conducted by each Party pursuant to the Development Plan and under the Research Agreement (each, a “Manufacturing Agreement”). As of the Execution Date, the Parties anticipate that any such Manufacturing Agreement shall incorporate commercially reasonable terms that are appropriate for a similarly situated manufacturing agreement, and shall include at least the following principles, as set forth below in [Sections 6.1(a) through (d)], and other material terms such as pricing, as the Parties shall mutually agree upon:

Upon Licensee’s request, Ovid will manufacture and supply, itself or through a Third Party contract manufacturer, all Drug Product for use in the Development and Commercialization of the Products under this Agreement and according to the Supply Agreement. All Drug Product supplied by Ovid to Licensee or Licensee Affiliate for use for Development and Commercial purposes shall be supplied at ​, provided that ​ (“Total Supply Price Threshold”). In case the Total Supply Price will be ​, the Cost of Good for such Drug Product will be ​ the Total Supply Price Threshold. For clarity, the Total Supply Price Threshold ​. Payment shall be due within ​ after Licensee’s receipt from Ovid of an invoice for such Drug Product. Drug Product shall be delivered EXW (Incoterms 2020) at supplier facility (or that Certain identified information marked with ​ has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

Manufacture and Supply. During the Term, the Supplier shall manufacture or have manufactured and shall supply to the Purchaser, its Affiliates and sub-licensees such quantities of the Package Configurations as the Purchaser may order from time to time in accordance with the terms of this Supply Agreement.

Manufacture and Supply. Providence shall be solely responsible for the Manufacture and supply, at its sole cost and expense, of all Collaboration Compounds and Products required for Development or Commercialization of Products including, without limitation, formulation, labeling and packaging, in accordance with the requirements of applicable Regulatory Authorities.

​ Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

The Parties are parties to and intend to enter into one or more agreements that will govern the terms of manufacture and supply of CTL Products and New CTL Products and Program ​, including specific ​ Products for clinical supply for use in development activities, including clinical trials to be conducted by each Party pursuant to the Development Plan and under the Research Agreement (each, a “Manufacturing Agreement”). As of the Execution Date, the Parties anticipate that any such additional Manufacturing Agreement shall incorporate commercially reasonable terms that are appropriate for a similarly situated manufacturing agreement, and shall include at least the following principles, as set forth below in [Sections 6.1(a) through (d)], and other material terms such as pricing, as the Parties shall mutually agree upon:

Manufacture and Supply. BioXcel shall use Commercially Reasonable Efforts to Manufacture or have Manufactured the BioXcel Compound in drug product form in reasonable quantities, within minimum lead times and at the points in time as agreed by the JDC for each Combined Therapy Trial. BioXcel or a Third Party conducting activities on behalf of BioXcel will package, label and distribute the BioXcel Compound for use in the Combined Therapy Trials, with associated costs and expenses (and any related taxes) of such activities to be split between the Parties in accordance with Sections 7.1 and 7.2(a)(ii). The cost of Manufacture and supply (including shipping, taxes and duty, if applicable) of BioXcel Compound for the Combined Therapy Trials shall be borne solely by BioXcel, and BioXcel shall bear the risk of loss for the BioXcel Compound. BioXcel shall also be responsible for the payment of any Third Party License Payments that may be due exclusively on the supply of BioXcel Compound for the Combined Therapy Trials. The BioXcel Compound shall be Manufactured in accordance with Applicable Law (including GMP) and shall be of similar quality to the BioXcel Compound used by BioXcel for its other clinical trials of the BioXcel Compound. BioXcel shall deliver to Nektar certificates of analysis, and any other documents specified in the Quality Agreement, including such documentation as is necessary to allow Nektar to compare the BioXcel Compound certificate of analysis to the BioXcel Compound specifications.

Upon Licensee’s request, Ovid will manufacture and supply, itself or through a Third Party contract manufacturer, all Drug Product for use in the Development and Commercialization of the Products under this Agreement and according to the Supply Agreement. All Drug Product supplied by Ovid to Licensee or Licensee Affiliate for use for Development and Commercial purposes shall be supplied at ​, provided that ​ (“Total Supply Price Threshold”). In case the Total Supply Price will be ​, the Cost of Good for such Drug Product ​ = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both # not material and # would be competitively harmful if publicly disclosed.